Mesenchymal stem cell membrane coating of gelatin nanospheres with drug release ability for inflammatory tissue targeting
Source abstract
Abstract
Abstract Improvements in drug delivery have been achieved using nanospheres to prolong drug efficacy, accelerate absorption, and target tissues with ongoing inflammation. Although nanospheres have numerous pharmacokinetic advantages their tissue-targeting ability is poor. In contrast, mesenchymal stem cells (MSC) accumulate in high numbers in inflammatory tissues via the interaction between CXC-chemokine receptor 4 (CXCR4) expressed on MSC and stromal cell-derived factor 1 (SDF-1) secreted during inflammation. Therefore, this study investigated coating gelatin nanospheres (GNS) with MSC membranes (MSC-GNS) by extrusion and ultrasonication methods to enhance their inflammatory tissue tropism. ζ-potential measurements, western blotting and single-particle analysis of MSC-GNS by flow cytometry demonstrated the GNS surface was successfully coated with MSC membranes. Dot blotting demonstrated the binding ability of CXCR4 for SDF-1 was retained by MSC-GNS but absent for MSC-membrane-free GNS. The blood clearance of MSC-GNS was examined by their intravenous injection into mice. Although MSC-GNS and GNS were retained during the early distribution phase, MSC-GNS had a higher retention than GNS during the later elimination phase. Finally, we investigated the tissue distribution of MSC-GNS by intravenous injection into a mouse model of liver fibrosis and their potential therapeutic effect on liver fibrosis. We found a higher accumulation of MSC-GNS in inflamed livers and higher blood retention compared with MSC-membrane-free GNS. Furthermore, MSC-GNS loaded with an anti-fibrotic agent (LSKL, a 4-amino acid peptide that inhibits fibrosis progression) had an enhanced therapeutic effect on liver fibrosis than uncoated nanoparticles. Therefore, MSC-GNS might be a drug carrier with inflammatory tissue targeting and controlled drug release abilities. Synopsis Table of Contents Graphic Mesenchymal stem cell membrane coated gelatin nanosphere as DDS nanocarrier
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Electrospun Nanofibers in Biomedical Applications · 3D Printing in Biomedical Research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (94)
Show source-provided references
1. An overview of drug delivery systems10.1007/978-1-4939-9798-5_1 ↗
2. Application of quality by design in optimization of nanoformulations: principle, perspectives and practices, Drug Deliv
3. Tailoring biomaterials for vaccine delivery10.1186/s12951-024-02758-0 ↗
4. J. Alipal, N.A.S. Mohd Pu'ad, T.C. Lee, N.H.M. Nayan, N. Sahari, H. Basri, M.I. Idris, H.Z. Abdullah, A review of gelatin: Properties, sources, process, applications, and commercialisation, Materials Today: Proceedings (2021) 240-250.10.1016/j.matpr.2020.12.922 ↗
5. Cationic cholesterol-modified gelatin as an in vitro siRNA delivery vehicle10.1039/C2MB25424G ↗
6. Preparation of cationized gelatin nanospheres incorporating molecular beacon to visualize cell apoptosis10.1038/s41598-018-33231-2 ↗
7. Gelatin nanospheres incorporating siRNA for controlled intracellular release10.1016/j.biomaterials.2012.08.032 ↗
8. All-in-one hydrogel patches with sprayed bFGF-loaded GelMA microspheres for infected wound healing studies10.1016/j.ijpharm.2024.124205 ↗
9. The hyaluronic acid-gelatin hierarchical hydrogel for osteoporotic bone defect repairment10.1016/j.ijbiomac.2024.133821 ↗
10. Curcumin and silver nanoparticles loaded antibacterial multifunctional pectin/gelatin films for food packaging applications10.1016/j.ijbiomac.2024.131248 ↗
11. Dialdehyde starch cross-linked aminated gelatin sponges with excellent hemostatic performance and biocompatibility10.1016/j.carbpol.2024.122326 ↗
12. Effect of fascia implantation and controlled release of basic fibroblast growth factor for muscle atrophy in rat laryngeal paralysis10.1177/01945998211052895 ↗
13. Live imaging of monocyte/macrophage differentiation with cationized gelatin nanospheres incorporating a molecular beacon10.1021/acsbiomaterials.2c01420 ↗
14. Preparation of biodegradable gelatin nanospheres with a narrow size distribution for carrier of cellular internalization of plasmid DNA10.1163/092050611X568214 ↗
15. The pro-inflammatory response of macrophages regulated by acid degradation products of poly(lactide-co-glycolide) nanoparticles10.1002/elsc.202100040 ↗
16. The uptake of PLGA micro or nanoparticles by macrophages provokes distinct in vitro inflammatory response10.1016/j.intimp.2011.05.014 ↗
17. The Anti-inflammatory effect of bovine bone-gelatin-derived peptides in LPS-induced RAW264.7 macrophages cells and dextran sulfate sodium-induced C57BL/6 mice10.3390/nu14071479 ↗
18. Collagen-derived dipeptides and amino acids have immunomodulatory effects in M1-differentiated RAW264.7 cells and PBMC10.3390/ijms24086925 ↗
19. Mesenchymal stem cells armed with DNA nanorobots as a modality for combination therapy of inflammatory bowel disease10.1021/acsami.4c08923 ↗
20. Roe-inspired stem cell microcapsules for inflammatory bowel disease treatment10.1073/pnas.2112704118 ↗
21. A charge-adhesive targeted DNA gel bandage for the precision treatment of inflammatory bowel disease
22. Exploring mesenchymal stem cells homing mechanisms and improvement strategies10.1093/stcltm/szae045 ↗
23. Mesenchymal stromal cell homing: mechanisms and strategies for improvement10.1016/j.isci.2019.05.004 ↗
24. Role of the CXCR4-SDF1-HMGB1 pathway in the directional migration of cells and regeneration of affected organs, World
25. Enhancing the migration ability of mesenchymal stromal cells by targeting the SDF-1/CXCR4 axis10.1155/2013/561098 ↗
26. Enhanced recruitment and hematopoietic reconstitution of bone marrow-derived mesenchymal stem cells in bone marrow failure by the SDF-1/CXCR4
27. Current progress of mesenchymal stem cell membrane-camouflaged nanoparticles for targeted therapy10.1016/j.biopha.2023.114451 ↗
28. Stem cell membrane-coated abiotic nanomaterials for biomedical applications10.1016/j.jconrel.2022.09.012 ↗
29. Recent advances in mesenchymal stem cell membrane-coated nanoparticles for enhanced drug delivery10.1039/D0BM01164A ↗
30. Bioengineered stem cell membrane functionalized nanocarriers for therapeutic targeting of severe hindlimb ischemia10.1016/j.biomaterials.2018.08.018 ↗
31. Self-assembly of stem cell membrane-camouflaged nanocomplex for microRNA-mediated repair of myocardial infarction injury10.1016/j.biomaterials.2020.120256 ↗
32. Chemotactic recruitment of genetically engineered cell membrane-camouflaged metal-organic framework nanoparticles for ischemic osteonecrosis treatment10.1016/j.actbio.2024.07.024 ↗
33. Cell culture design for homogeneous proliferation of cells in three-dimensional nonwoven polymer scaffolds10.1080/09205063.2023.2265623 ↗
34. Preparation of antibody-immobilized gelatin nanospheres incorporating a molecular beacon to visualize the biological function of macrophages10.1016/j.reth.2019.12.009 ↗
35. Development of targeted drug delivery system for the treatment of SARS-CoV-2 using aptamer-conjugated gold nanoparticles10.3390/pharmaceutics16101288 ↗
36. Mannose-functionalized chitosan-coated PLGA nanoparticles for brain-targeted codelivery of CBD and BDNF for the treatment of Alzheimer's disease10.1021/acschemneuro.4c00392 ↗
37. Macromolecular therapeutics in cancer treatment: the EPR effect and beyond10.1016/j.jconrel.2012.04.038 ↗
38. Growth inhibition of pancreatic cancer by targeted delivery of gemcitabine via fucoidan-coated pH-sensitive liposomes10.1016/j.ijbiomac.2024.134517 ↗
39. Cell membrane-coated nanoparticles: a novel multifunctional biomimetic drug delivery system, drug Deliv
40. Advances in biomimetic nanomaterial delivery systems: harnessing nature's inspiration for targeted drug delivery10.1039/D4TB00565A ↗
41. Cell membrane-based biomimetic nanoparticles and the immune system: immunomodulatory interactions to therapeutic applications10.3389/fbioe.2020.00627 ↗
42. Red blood cell membrane-camouflaged nanoparticles loaded with AIEgen and Poly(I : C) for enhanced tumoral photodynamic-immunotherapy10.1093/nsr/nwab039 ↗
43. A biomimetic nanocarrier strategy targets ferroptosis and efferocytosis during myocardial infarction10.2147/IJN.S461212 ↗
44. Homologous tumor cell-derived biomimetic nano-trojan horse integrating chemotherapy with genetherapy for boosting triple-negative breast cancer therapy10.1021/acsami.4c08842 ↗
45. Modified desolvation method enables simple one-step synthesis of gelatin nanoparticles from different gelatin types with any bloom values10.3390/pharmaceutics13101537 ↗
46. Advances in cell membrane-based biomimetic nanodelivery systems for natural products10.1080/10717544.2024.2361169 ↗
47. On the design of cell membrane-coated nanoparticles to treat inflammatory conditions10.1039/D4NH00457D ↗
48. Immuno-engineered nanodecoys for the multi-target anti-inflammatory treatment of autoimmune diseases10.1002/adma.202108817 ↗
49. Surface Functionalization of Polymeric Nanoparticles with Umbilical Cord-Derived Mesenchymal Stem Cell Membrane for Tumor-Targeted Therapy10.1021/acsami.8b05363 ↗
50. Engineering cell membrane-based nanotherapeutics to target inflammation
51. Cell membrane coating nanotechnology10.1002/adma.201706759 ↗
52. Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform10.1073/pnas.1106634108 ↗
53. Imaging of liposomes by transmission electron microscopy10.1007/978-1-4939-7352-1_8 ↗
54. Time course of myocardial stromal cell-derived factor 1 expression and beneficial effects of intravenously administered bone marrow stem cells in rats with experimental myocardial infarction10.1007/s00395-005-0521-z ↗
55. CXCR4 signaling in the regulation of stem cell migration and development10.1016/j.jneuroim.2008.04.008 ↗
56. Stromal-cell-derived factor (SDF) 1-alpha overexpression promotes bone regeneration by osteogenesis and angiogenesis in osteonecrosis of the femoral head10.1159/000489684 ↗
57. MiR-4458-loaded gelatin nanospheres target COL11A1 for DDR2/SRC signaling pathway inactivation to suppress the progression of estrogen receptor-positive breast cancer10.1039/D2BM00543C ↗
58. Macrophage membrane-coated nanoparticles for the delivery of Natamycin exhibit increased antifungal and anti-inflammatory activities in fungal keratitis10.1021/acsami.4c11366 ↗
59. Plasma terminal half-life10.1111/j.1365-2885.2004.00600.x ↗
60. CD47/SIRPα axis: bridging innate and adaptive immunity10.1136/jitc-2022-004589 ↗
61. Biomimetic metal-organic framework gated nanoplatform for sonodynamic therapy against extensively drug resistant bacterial lung infection
62. Reduction of oxidative stress and excitotoxicity by mesenchymal stem cell biomimetic co-delivery system for cerebral ischemia-reperfusion injury treatment
63. Biomimetic nanotherapies: red blood cell based core-shell structured nanocomplexes for atherosclerosis management
64. Combined strategies for effective cancer immunotherapy with a novel anti-CD47 monoclonal antibody10.1007/s00262-021-02989-2 ↗
65. The advances in targeting CD47/SIRPα “do not eat me” axis and their ongoing challenges as an anticancer therapy10.18632/oncotarget.28607 ↗
66. Adipose-derived stem-cell-membrane-coated PLGA-PEI nanoparticles promote wound healing via efficient delivery of miR-2110.3390/pharmaceutics16091113 ↗
67. Liver fibrosis: mechanistic concepts and therapeutic perspectives10.3390/cells9040875 ↗
68. Correlation between SDF-1α, CD34 positive hematopoietic stem cells and CXCR4 expression with liver fibrosis in CCl4 rat model10.1186/s12876-023-02932-y ↗
69. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review10.1016/S0168-3659(99)00248-5 ↗
70. Nanoparticle technologies for liver targeting and their applications in liver diseases10.3389/fbioe.2025.1661872 ↗
71. K. Xiao Ling, L. Peng, Z. Jian Feng, C. Wei, Y. Wei Yan, S. Nan, G. Cheng Qi, W. Zhi Wei, Stromal Derived Factor-1/CXCR4 Axis Involved in Bone Marrow Mesenchymal Stem Cells Recruitment to Injured Liver, Stem Cells Int 2016 (2016) 8906945.10.1155/2016/8906945 ↗
72. Hepatic stellate cells promote liver metastasis of colon cancer cells by the action of SDF-1/CXCR4 axis10.1245/s10434-009-0599-x ↗
73. Hepatic recruitment of the inflammatory Gr1+ monocyte subset upon liver injury promotes hepatic fibrosis10.1002/hep.22950 ↗
74. Mesenchymal stem cell homing to improve therapeutic efficacy in liver disease10.1186/s13287-022-02858-4 ↗
75. CCR2-overexpressing mesenchymal stem cells targeting damaged liver enhance recovery of acute liver failure10.1186/s13287-022-02729-y ↗
76. CXCL16/CXCR6 axis in adipocytes differentiated from human adipose derived mesenchymal stem cells regulates macrophage polarization10.3390/cells10123410 ↗
77. CXCR6 recruits Th2 cells and promotes liver fibrosis in schistosomiasis japonica10.1097/HC9.0000000000000784 ↗
78. Human mesenchymal stem cells are recruited to injured liver in a β1-integrin and CD44 dependent manner10.1002/hep.25716 ↗
79. Stem cell membrane-coated nanogels for highly efficient in vivo tumor targeted drug delivery10.1002/smll.201600624 ↗
80. The activation sequence of thrombospondin-1 interacts with the latency-associated peptide to regulate activation of latent transforming growth factor-beta10.1074/jbc.274.19.13586 ↗
81. In silico characterization of the interaction between LSKL peptide, a LAP-TGF-beta derived peptide, and ADAMTS110.1016/j.compbiolchem.2016.01.012 ↗
82. Effect of LSKL peptide on thrombospondin 1-mediated transforming growth factor β signal activation and liver regeneration after hepatectomy in an experimental model10.1002/bjs.9765 ↗
83. LSKL, a peptide antagonist of thrombospondin-1, attenuates renal interstitial fibrosis in rats with unilateral ureteral obstruction10.1007/s12272-010-0213-6 ↗
84. LSKL peptide alleviates subarachnoid fibrosis and hydrocephalus by inhibiting TSP1-mediated TGF-β1 signaling activity following subarachnoid hemorrhage in rats10.3892/etm.2016.3640 ↗
85. Histological and molecular evaluation of liver biopsies: a practical and updated review10.3390/ijms26167729 ↗
86. The value of alpha-SMA in the evaluation of hepatic fibrosis severity in hepatitis B infection and cirrhosis development: a histopathological and immunohistochemical study10.1111/j.1365-2559.2005.02226.x ↗
87. Extracellular vesicle mimetics engineered from mesenchymal stem cells and curcumin promote fibrosis regression in a mouse model of thioacetamide-induced liver fibrosis10.1016/j.reth.2024.10.005 ↗
88. Mesenchymal stromal cell-derived membrane particles: a novel cell-free therapy for inflammatory bowel diseases10.1016/j.intimp.2023.110076 ↗
89. Targeting Myd88 using peptide-loaded mesenchymal stem cell membrane-derived synthetic vesicles to treat systemic inflammation10.1186/s12951-022-01660-x ↗
90. Mesenchymal stem cells improve mouse non-heart-beating liver graft survival by inhibiting Kupffer cell apoptosis via TLR4-ERK1/2-Fas/FasL-caspase3 pathway regulation10.1186/s13287-016-0416-y ↗
91. Non-clinical assessment of safety, biodistribution and tumorigenicity of human mesenchymal stromal cells10.1016/j.toxrep.2021.11.016 ↗
92. Biomimetic mesenchymal stem cell membrane-coated nanoparticle delivery of MKP5 inhibits hepatic fibrosis through the IRE/XBP1 pathway10.1186/s12951-024-03029-8 ↗
93. Gelatinase-sensitive nanoparticles loaded with photosensitizer and STAT3 inhibitor for cancer photothermal therapy and immunotherapy10.1186/s12951-021-01125-7 ↗
94. Biocompatible gelatin nanoparticles for tumor-targeted delivery of polymerized siRNA in tumor-bearing mice10.1016/j.jconrel.2013.09.002 ↗